Results 201 to 210 of about 12,531 (249)
Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis [PDF]
New England Journal of Medicine, 2016 BACKGROUND Levosimendan is a calcium-sensitizing drug with inotropic and other properties that may improve outcomes in patients with sepsis. METHODS We conducted a double-blind, randomized clinical trial to investigate whether levosimendan reduces the ...
Anthony C Gordon +2 more
exaly +4 more sources
Journal of Pediatric Intensive Care, 2015 We designed this review to examine the mechanism of action of levosimendan (Simdax®, Orion Pharma, Espoo, Finland) and its current clinical application in critically ill adults and children with acutely decompensated severe congestive heart failure and who require inotropic support.
Asher, Levin, Gideon, Paret
openaire +3 more sources
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION‐HEART multicentre randomised trial [PDF]
European Journal of Heart Failure, 2018 [Abstract] Aims. The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with ...
Alessandro Sionis, Domingo Pascual-Figal
exaly +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2001
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure. At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands.
D P, Figgitt, P S, Gillies, K L, Goa
+5 more sources
Current Pharmaceutical Design, 2013
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources
During the last years an increasing number of patients with high perioperative risk and decreased left ventricular function are referred to cardiac and non-cardiac surgery. In this subgroup of patients, heart failure is the major cause of perioperative morbidity and mortality. In order to prevent and treat this type of complications several therapeutic
Andrea, Rognoni +7 more
openaire +2 more sources